Pull to refresh
Logo
FDA approves Roche's oral breast cancer pill Wilserdly

FDA approves Roche's oral breast cancer pill Wilserdly

New Capabilities

The daily pill, paired with everolimus, extended median progression-free survival to 10 months from 5.5 in patients with ESR1 mutations. A second approval, for earlier-stage disease, is due Nov. 30.

Overview

Updated 1 hour ago

The Food and Drug Administration approved giredestrant, which Roche sells as Wilserdly, on Nov. 16. It is a once-daily pill taken with everolimus for adults whose ER-positive, HER2-negative breast cancer carries an ESR1 mutation and has returned after hormone therapy.

In the trial that won the approval, the pair pushed median progression-free survival to 10 months from 5.5 in 207 patients with those mutations. Roche priced it at $22,500 a month and is waiting on a second FDA decision, due Nov. 30, on treating earlier-stage disease.

Why it matters

Up to 40% of metastatic breast cancer patients develop ESR1 mutations that defeat standard hormone pills. Roche's daily regimen targets them.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$22,500
Monthly list price
Roche's price for a 30-day supply, which RBC analysts called comparable to similar breast cancer medicines.
0.38
Progression-free survival hazard ratio
Risk of progression or death for giredestrant plus everolimus versus physician's-choice endocrine therapy plus everolimus, in ESR1-mutant patients.
10 vs 5.5
Median months without progression
Giredestrant plus everolimus versus standard endocrine therapy plus everolimus in the ESR1-mutant group.
40%
Share of HR-positive metastatic patients who develop ESR1 mutations
These mutations let tumors grow without estrogen, which blunts aromatase inhibitors.
$14B
RBC's peak annual sales estimate
Analyst Trung Huynh's projection, most of it from earlier-line use.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

3 events Latest: Yesterday
  1. Roche prices Wilserdly at $22,500 a month

    Latest Pricing

    A Roche spokesperson confirmed the list price, which RBC analysts called comparable to similar breast cancer medicines.

  2. FDA approves Wilserdly for ESR1-mutated advanced breast cancer

    Approval

    The agency cleared giredestrant plus everolimus for patients whose disease returned after hormone therapy, and authorized a companion blood test.

  3. Roche flags second FDA decision due Nov. 30

    Regulatory

    The adjuvant filing, based on the lidERA trial, is under Priority Review and would cover stage I-III disease.

Scenarios

1

FDA clears Wilserdly for early-stage breast cancer

Likely Resolves by Nov 30, 2026

Discussed by: Roche, which disclosed the Nov. 30 PDUFA date; the filing is under Priority Review

Roche filed lidERA results for stage I-III disease and the FDA accepted the application under Priority Review, which shortens the standard review clock. Approval would make Wilserdly the first new adjuvant endocrine therapy in more than 20 years, by Roche's account, and open the larger market of patients treated after surgery.

2

Adjuvant decision slips past the November deadline

Possible Resolves by End of 2026

Discussed by: No public forecaster has called for a delay; included because a PDUFA date is a target, not a guarantee

The FDA can extend a review without announcing it in advance, and the agency has not published its assessment of the lidERA data. A delay would leave Roche selling only in advanced disease into 2027, with the $14 billion sales case pushed back.

3

Wilserdly becomes Roche's best-selling drug

Uncertain Resolves by End of 2030

Discussed by: Roche Pharmaceuticals head Teresa Graham and RBC analyst Trung Huynh, who projects up to $14 billion in peak annual sales

Roche and Huynh expect most Wilserdly revenue to come from earlier-line use, which requires the adjuvant approval and enough room left by CDK 4/6 inhibitors. Jefferies' Michael Leuchten doubts the class's addressable market is as large as headline patient counts suggest.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

Two decades to 2026

Fulvestrant, the injectable standard

Degrading the estrogen receptor has meant a clinic-administered injection of fulvestrant, a drug BioPharma Dive describes as decades old. Oral SERDs were designed to replace it with a once-daily pill.

Then

The first oral SERDs reached market only for ESR1-mutant patients, so fulvestrant stayed in wide use.

Now

No oral SERD has displaced the injection. Roche's drug is the first in the class to show a benefit in the adjuvant setting.

Why this matters now

Wilserdly's sales case rests on moving injection patients to a pill and on treating patients fulvestrant cannot reach.

Through 2026

Oral SERDs fall short in the first line

Eli Lilly, AstraZeneca and Roche all brought oral SERDs to market, each cleared only for tumors with ESR1 mutations. A few, including Roche's, failed trials testing first-line use.

Then

Labels stayed narrow and the class's commercial ceiling became the central question for analysts.

Now

Jefferies' Michael Leuchten wrote in October 2026 that the debate is now about where the drugs fit, not whether they work.

Why this matters now

It explains why the Nov. 30 adjuvant decision matters more to Roche than the approval it just received.

Two decades to 2026

Two decades without a new adjuvant endocrine therapy

After surgery, hormone-positive breast cancer has been treated with tamoxifen and aromatase inhibitors. Roche says no new drug has entered that setting in more than 20 years.

Then

The FDA's decision on the lidERA filing is due Nov. 30, 2026.

Now

Unknown. Approval would give Roche the earlier-line market its sales forecast depends on.

Why this matters now

Most of the projected $14 billion in peak sales would come from earlier-line use.

Sources

(5)